Induction of tubulin polymerization and apoptosis in malignant mesothelioma cells by a new compound JBIR-23

Cancer Letters

Volumn 300, Issue 2, 2011, Pages 189-196

  Hwang, Ji Hwan ^a   Takagi, Motoki ^b   Murakami, Hideki ^c   Sekido, Yoshitaka ^c,d   Shin ya, Kazuo ^a  

^a NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY AIST   (Japan)

^b Koto ku   (Japan)

^c AICHI CANCER CENTER HOSPITAL   (Japan)

^d NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

JBIR 23; Malignant pleural mesothelioma; Paclitaxel; Tubulin polymerization

Indexed keywords

CASPASE; CYTOTOXIC AGENT; FAS ASSOCIATED DEATH DOMAIN PROTEIN; JBIR 23; MITOGEN ACTIVATED PROTEIN KINASE P38; PACLITAXEL; STRESS ACTIVATED PROTEIN KINASE; TUBULIN; UNCLASSIFIED DRUG; VINBLASTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER PREVENTION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; MALIGNANT MESOTHELIOMA; MICROTUBULE ASSEMBLY; NONHUMAN; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; STREPTOMYCES; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZOFURANS; CELL LINE, TUMOR; CELL SEPARATION; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOBLOTTING; MESOTHELIOMA; MICE; MICE, NUDE; TUBULIN; TUBULIN MODULATORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS MUSCULUS; STREPTOMYCES SP.;

EID: 78649632047     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.10.005     Document Type: Article

References (33)

1. Carbone M., Kratzke R.A., Testa J.R. The pathogenesis of mesothelioma. Semin. Oncol. 2002, 29:2-17.
2. Mossman B.T., Kamp K.W., Weitzman S.A. Mechanisms of carcinogenesis and clinical features of asbestos-associated cancers. Cancer Invest. 1996, 14:466-480.
3. Robinson B.W., Lake R.A. Advances in malignant mesothelioma. New Engl. J. Med. 2005, 353:1591-1603.
4. Tsiouris A., Walesby R.K. Malignant pleural mesothelioma: current concepts in treatment. Nat. Clin. Pract. Oncol. 2007, 4:344-352.
5. Weder W., Kestenholz P., Taverna C., Bodis S., Lardinois D., Jerman M., Stahel R.A. Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. J. Clin. Oncol. 2004, 22:3451-3457.
6. Sekido Y. Genomic abnormalities and signal transduction dysregulation in malignant mesothelioma cells. Cancer Sci. 2010, 1:1-6.
7. Palumbo C., Bei R., Procopio A., Modesti A. Molecular targets and targeted therapies for malignant mesothelioma. Curr. Med. Chem. 2008, 15:855-867.
8. Motohashi K., Hwang J.H., Sekido Y., Takagi M., Shin-ya K. JBIR-23 and -24, novel anticancer agents from Streptomyces sp. AK-AB27. Org. Lett. 2009, 11:285-288.
9. Usami N., Fukui T., Kondo M., Taniguchi T., Yokoyama T., Mori S., Yokoi K., Horio Y., Shimokata K., Sekido Y., Hida T. Establishment and characterization of four malignant pleural mesothelioma cell lines from Japanese patients. Cancer Sci. 2006, 97:387-394.
10. Blagosklonny M.V., Schulte T.W., Nguyen P., Mimnaugh E.G., Trepel J., Neckers L. Taxol induction of p21WAF1 and p53 requires c-raf-1. Cancer Res. 1995, 55:4623-4626.
11. Adusumilli P.S., Stiles B.M., Chan M.K., Mullerad M., Eisenberg D.P., Ben-Porat L., Huq R., Rusch V.W., Fong Y. Imaging and therapy of malignant pleural mesothelioma using replication-competent herpes simplex viruses. J. Gene. Med. 2006, 8:603-615.
12. Stewart J.H., Nguyen D.M., Chen G.A., Schrump D.S. Induction of apoptosis in malignant pleural mesothelioma cells by activation of the Fas (Apo-1/CD95) death-signal pathway. J. Thorac. Cardiovasc. Surg. 2002, 123:295-302.
13. Mandal M., Maggirwar S.B., Sharma N., Kaufmann S.H., Sun S.C., Kumar R. Bcl-2 prevents CD95 (Fas/Apo-1)-induced degradation of lamin B and poly(ADP-ribose) polymerase and restores the NF-kappaB signalling pathway. J. Biol. Chem. 1996, 271:30354-30359.
14. Mielgo A., Torres V.A., Clair K., Barbero S., Stupack D.G. Paclitaxel promotes a caspase 8-mediated apoptosis through death effector domain association with microtubules. Oncogene 2009, 28:3551-3562.
15. S Bacus S., Gudkov A.V., Lowe M., Lyass L., Yung Y., Komarov A.P., Keyomarsi K., Yarden Y., Seger R. Taxol-induced apoptosis depends on MAP kinase pathway (ERK and p38) and is independent of p53. Oncogene 2001, 20:147-155.
16. Shimada K., Matsuyoshi S., Nakamura M., Ishida E., Kishi M., Konishi N. Phosphorylation of FADD is critical for sensitivity to anticancer drug-induced apoptosis. Carcinogenesis 2004, 25:1089-1097.
17. Yujiri T., Fanger G.R., Garrington T.P., Schlesinger T.K., Gibson S., Johnson G.L. MEK kinase 1 (MEKK1) transduces c-Jun NH2-termianl kinase activation in response to changes in the microtubule cytoskeletone. J. Biol. Chem. 1998, 274:12605-12610.
18. Scaffidi C., Volkland J., Blomberg I., Hoffmann I., Krammer P.H., Peter M.E. Phosphorylation of FADD/MORT1 at serine 194 and association with a 70-kDa cell cycle-regulated protein kinase. J. Immunol. 2000, 164:1236-1242.
19. Skwarczynski M., Hayashi Y., Kiso Y. Paclitaxel prodrugs: toward smarter delivery of anticancer agents. J. Med. Chem. 2006, 49:7253-7269.
20. Kingston D.G. Tubulin-interactive natural products as anticancer agents. J. Nat. Prod. 2009, 72:507-515.
21. Blagosklonny M.V., Schulte T., Nguen P., Trepel J., Neckers L.M. Taxol-induced apoptosis and phosphorylation of bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway. Cancer Res. 1993, 56:1851-1854.
22. Ding A., Sanchez E., Nathan C.F. Taxol shares the ability of bacterial lipopolysaccharide to induce tyrosine phosphorylation of microtubule-associated protein kinase. J. Immunol. 1993, 151:5596-5602.
23. Lee L.F., Li G., Templeton D.J., Ting J.P. Paclitaxel (Taxol)-induced gene expression and cell death are both mediated by the activation of c-Jun NH2-terminal kinase (JNK/SAPK). J. Biol. Chem. 1998, 273:28253-28260.
24. Inamdar G.S., Madhunapantula S.V., Robertson G.P. Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail. Biochem. Pharmacol. 2010, 80:624-637.
25. Widmann C., Gerwins P., Johnson N.L., Jarpe M.B., Johnson G.L. MEK kinase 1, a substrate for DEVD-directed caspases, is involved in genotoxin-induced apoptosis. Mol. Cell. Biol. 1998, 18:2416-2429.
26. Gibson S., Widmann C., Johnson G.L. Differential involvement of MEK kinase 1 (MEKK1) in the induction of apoptosis in response to microtubule-targeted drugs versus DNA damaging agents. J. Biol. Chem. 1999, 274:10916-10922.
27. Kumar R., Gururaj A.E., Barnes C.J. p21-activated kinases in cancer. Nat. Rev. Cancer 2006, 6:459-471.
28. Kissil J.L., Wilker E.W., Johnson K.C., Eckman M.S., Yaffe M.B., Jacks T. Merlin, the product of the Nf2 tumor suppressor gene, is an inhibitor of the p21-activated kinase, Pak1. Mol. Cell 2003, 12:841-849.
29. Zhang J., Kabra N.H., Cado D., Kang C., Winoto A. FADD-deficient T cells exhibit a disaccord in regulation of the cell cycle machinery. J. Biol. Chem. 2001, 276:29815-29818.
30. Hua Z.C., Shon S.J., Kang C., Cado D., Winoto A. A function of Fas-associated death domain protein in cell cycle progression localized to a single amino acid at its C-terminal region. Immunity 2003, 18:513-521.
31. Matsuyoshi S., Shimada K., Nakamura M., Ishida E., Konishi N. FADD phosphorylation is critical for cell cycle regulation in breast cancer cells. Br. J. Cancer 2006, 94:532-539.
32. Liu W.H., Cheng Y.C., Chang L.S. ROS-mediated p38alpha MAPK activation and ERK inactivation responsible for upregulation of Fas and FasL and autocrine Fas-mediated cell death in Taiwan cobra phospholipase A(2)-treated U937 cells. J. Cell. Physiol. 2009, 219:642-651.
33. Wang T.H., Wang H.S., Ichijo H., Giannakakou P., Foster J.S., Fojo T., Wimalasena J. Microtubule-interfering agents activate c-Jun N-terminal kinase/stress-activated protein kinase through both Ras and apoptosis signal-regulating kinase pathways. J. Biol. Chem. 1998, 273:4928-4936.